
Amanda focuses her practice on securities transactions, public offerings, and other general corporate matters. She represents clients in different industries, primarily life sciences. Amanda has experience with representing clients in a variety of capital markets transactions, including initial public offerings, reverse mergers, follow-on offerings, and at-the-market offerings.
During law school, Amanda served as a legal extern with the Victim Rights Law Center in Boston where she helped sexual assault survivors with their legal needs, including U visa applications and asylum applications. She was also a member of the International Law Journal. Amanda served as treasurer of the Latin American Law Students Association and was a member of the Asian Pacific American Law Students Association.
Prior to attending law school, Amanda worked as a paralegal officer with a Boston-based investment bank, with a focus on regulatory filings and board governance for investment management companies.
viewpoints
SEC Roundtable on Executive Compensation Disclosure
July 23, 2025 | Advisory | By Amanda Mei, Daniel T. Kajunski, Anne Bruno
The SEC held a roundtable at the SEC’s headquarters in Washington, DC on June 26, 2025 to discuss possible changes to the Commission’s requirements for executive compensation disclosure.
The OASB Annual Report to Congress for Fiscal Year 2020
March 15, 2021 | Blog | By Amanda Mei
SEC Amends MD&A and Other Financial Disclosure Rules
February 5, 2021 | Alert | By Daniel T. Kajunski, Amanda Mei
SEC Guidance on Key Performance Indicators and Metrics in MD&A and Three New MD&A C&DIs
February 26, 2020 | Advisory | By Daniel T. Kajunski, Amanda Mei
News & Press
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Mintz Advises Cardurion Pharmaceuticals in Investment of up to $300 Million from Bain Capital
November 02, 2021
Recognition & Awards
Richard Mintz Summer Associate Diversity Scholar (2017)